353 related articles for article (PubMed ID: 29865876)
1. Causality assessment of serious and severe adverse events following immunization in India: a 4-year practical experience.
Singh AK; Wagner AL; Joshi J; Carlson BF; Aneja S; Boulton ML
Expert Rev Vaccines; 2018 Jun; 17(6):555-562. PubMed ID: 29865876
[TBL] [Abstract][Full Text] [Related]
2. Application of the revised WHO causality assessment protocol for adverse events following immunization in India.
Singh AK; Wagner AL; Joshi J; Carlson BF; Aneja S; Boulton ML
Vaccine; 2017 Jul; 35(33):4197-4202. PubMed ID: 28648545
[TBL] [Abstract][Full Text] [Related]
3. Deaths reported to national surveillance for adverse events following immunization in China, 2010-2015.
Wu W; Liu D; Nuorti JP; Li K; Xu D; Ye J; Zheng J; Cao L; Wang H
Vaccine; 2019 Feb; 37(9):1182-1187. PubMed ID: 30709723
[TBL] [Abstract][Full Text] [Related]
4. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use.
Tozzi AE; Asturias EJ; Balakrishnan MR; Halsey NA; Law B; Zuber PL
Vaccine; 2013 Oct; 31(44):5041-6. PubMed ID: 24021304
[TBL] [Abstract][Full Text] [Related]
5. Systematic causality assessment of adverse events following HPV vaccines: Analysis of current data from Apulia region (Italy).
Tafuri S; Fortunato F; Gallone MS; Stefanizzi P; Calabrese G; Boccalini S; Martinelli D; Prato R
Vaccine; 2018 Feb; 36(8):1072-1077. PubMed ID: 29358055
[TBL] [Abstract][Full Text] [Related]
6. Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India.
Gandhi AP; Venkatesh U; Murali N
Indian Heart J; 2023; 75(2):139-144. PubMed ID: 36863611
[TBL] [Abstract][Full Text] [Related]
7. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India.
Joshi J; Das MK; Polpakara D; Aneja S; Agarwal M; Arora NK
Indian J Pediatr; 2018 Feb; 85(2):139-148. PubMed ID: 29170922
[TBL] [Abstract][Full Text] [Related]
8. Adverse events following immunization: is this time for the use of WHO causality assessment?
Tafuri S; Gallone MS; Calabrese G; Germinario C
Expert Rev Vaccines; 2015 May; 14(5):625-7. PubMed ID: 25805053
[TBL] [Abstract][Full Text] [Related]
9. Adverse events following immunization: real causality and myths.
Principi N; Esposito S
Expert Opin Drug Saf; 2016 Jun; 15(6):825-35. PubMed ID: 26986067
[TBL] [Abstract][Full Text] [Related]
10. Adverse events following immunization in children: retrospective analysis of spontaneous reports over a decade.
Aagaard L; Hansen EW; Hansen EH
Eur J Clin Pharmacol; 2011 Mar; 67(3):283-8. PubMed ID: 21079934
[TBL] [Abstract][Full Text] [Related]
11. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
Masuka JT; Khoza S
BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
[TBL] [Abstract][Full Text] [Related]
12. Adverse event following immunization (AEFI) surveillance in India, position paper of Indian Academy of Pediatrics,2013.
Chitkara AJ; Thacker N; Vashishtha VM; Bansal CP; Gupta SG
Indian Pediatr; 2013 Aug; 50(8):739-41. PubMed ID: 24036641
[TBL] [Abstract][Full Text] [Related]
13. Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017.
Yoon D; Kim JH; Lee H; Shin JY
Yonsei Med J; 2020 Jul; 61(7):623-630. PubMed ID: 32608206
[TBL] [Abstract][Full Text] [Related]
14. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
Loughlin AM; Marchant CD; Adams W; Barnett E; Baxter R; Black S; Casey C; Dekker C; Edwards KM; Klein J; Klein NP; LaRussa P; Sparks R; Jakob K
Vaccine; 2012 Nov; 30(50):7253-9. PubMed ID: 23063829
[TBL] [Abstract][Full Text] [Related]
15. [Surveillance of adverse events following immunization in Minhang district of Shanghai from 2007 to 2010].
Zhang LP; Yu F; Jin BF; Wang Y; Xu HL; DU Y
Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):859-64. PubMed ID: 23302620
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of adverse events following immunisation: Australia 2002 to 2003.
Lawrence G; Boyd I; McIntyre P; Isaacs D
Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of adverse events following immunisation: Australia, 2000-2002.
Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D
Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057
[TBL] [Abstract][Full Text] [Related]
18. Strengthening of causality assessment of adverse events following immunization in the WHO South East Asia and Western Pacific regions: Lessons from the 2014 SEAR inter-country workshop.
MacDonald NE; Guichard S; Amarasinghe A; Balakrishnan MR;
Vaccine; 2015 Nov; 33(48):6902-7. PubMed ID: 25617790
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of adverse events following immunization during pregnancy and the newborn period.
Fulton TR; Narayanan D; Bonhoeffer J; Ortiz JR; Lambach P; Omer SB
Vaccine; 2015 Nov; 33(47):6453-65. PubMed ID: 26413879
[TBL] [Abstract][Full Text] [Related]
20. Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023.
Stefanizzi P; Di Lorenzo A; Martinelli A; Moscara L; Stella P; Ancona D; Tafuri S
Vaccine; 2023 Nov; 41(48):7096-7102. PubMed ID: 37891052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
